Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1395 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7435.084 | 1.0948 | 1.2208 | 0.8646 | |
| HCC1395 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7435.084 | 1.0167 | 1.0387 | 0.8646 | |
| HCC1395 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7435.084 | 0.8912 | 0.7505 | 0.8646 | |
| HCC1395 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7435.084 | 0.9153 | 0.8055 | 0.8646 | |
| HCC1395 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7435.084 | 1.0461 | 1.1069 | 0.8646 | |
| HCC1395 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.000853 | uM | 7436.085 | 0.9852 | 0.9765 | 1.2621 | |
| HCC1395 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00427 | uM | 7436.085 | 1.0336 | 1.0530 | 1.2621 | |
| HCC1395 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0213 | uM | 7436.085 | 1.0032 | 1.0050 | 1.2621 | |
| HCC1395 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.107 | uM | 7436.085 | 1.0318 | 1.0502 | 1.2621 | |
| HCC1395 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.533 | uM | 7436.085 | 1.0489 | 1.0772 | 1.2621 | |
| HCC1395 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 2.67 | uM | 7436.085 | 1.0255 | 1.0402 | 1.2621 | |
| HCC1395 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 13.3 | uM | 7436.085 | 1.0144 | 1.0229 | 1.2621 | |
| HCC1395 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 66.7 | uM | 7436.085 | 0.3550 | -0.1196 | 1.2621 | |
| HCC1395 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 333 | uM | 7436.085 | 0.0069 | -0.9613 | 1.2621 | |
| HCC1419 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7437.084 | 0.9775 | 0.8981 | 0.4343 | |
| HCC1419 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7437.084 | 0.9846 | 0.9296 | 0.4343 | |
| HCC1419 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7437.084 | 0.9702 | 0.8653 | 0.4343 | |
| HCC1419 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7437.084 | 0.9708 | 0.8682 | 0.4343 | |
| HCC1419 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7437.084 | 0.9874 | 0.9425 | 0.4343 | |
| HCC1419 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7437.084 | 0.9752 | 0.8875 | 0.4343 | |
| HCC1419 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7437.084 | 0.8970 | 0.5570 | 0.4343 | |
| HCC1419 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7437.084 | 0.9937 | 0.9712 | 0.4343 | |
| HCC1419 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7437.084 | 0.9841 | 0.9273 | 0.4343 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7441.084 | 0.9656 | 0.9188 | 0.8431 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7441.084 | 1.0308 | 1.0733 | 0.8431 |